hydroxychloroquine has been researched along with Metabolic Diseases in 2 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Metabolic Diseases: Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine (HCQ) has been shown to improve survival rates in other inflammatory diseases." | 6.58 | Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. ( Barnetche, T; Combe, B; Gaujoux-Viala, C; Hua, C; Lukas, C; Morel, J; Rempenault, C, 2018) |
| "Hydroxychloroquine (HCQ) has been shown to improve survival rates in other inflammatory diseases." | 2.58 | Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. ( Barnetche, T; Combe, B; Gaujoux-Viala, C; Hua, C; Lukas, C; Morel, J; Rempenault, C, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Khunti, S | 1 |
| Khunti, N | 1 |
| Seidu, S | 1 |
| Khunti, K | 1 |
| Rempenault, C | 1 |
| Combe, B | 1 |
| Barnetche, T | 1 |
| Gaujoux-Viala, C | 1 |
| Lukas, C | 1 |
| Morel, J | 1 |
| Hua, C | 1 |
1 review available for hydroxychloroquine and Metabolic Diseases
| Article | Year |
|---|---|
Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, | 2018 |
1 other study available for hydroxychloroquine and Metabolic Diseases
| Article | Year |
|---|---|
Therapeutic uncertainties in people with cardiometabolic diseases and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19).
Topics: Aged; Cardiovascular Diseases; Chloroquine; Clinical Trials as Topic; COVID-19; Delivery of Health C | 2020 |